United States-based Apotex Corp announced on Tuesday that it has launched its Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane, in the United States.

The product is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.

Peter Hardwick, Apotex Corp president, said, 'We are proud to provide Americans with a generic option of this important medication. This launch provides patients with a high-quality medication at an affordable price.'